Because anti-CD19/CD28 CAR is more widely used in CAR-T cell therapy, we modified CIKZ cells with anti-CD19/CD28 mRNA CAR to demonstrate the in vivo tumor-killing efficiency of mRNA CAR-modified CIKZ cells. Here, CD19 is linked to neoplasm.